About Senolytics & Cellular Rejuvenation
The Senolytics & Cellular Rejuvenation category is part of the Longevity & Human Enhancement market map, tracking 13 companies building in this segment. Senolytics, epigenetic reprogramming, exoskeletons, nootropics, and implantable devices pushing the boundaries of human lifespan and performance. Curated by Hartmann Capital's venture research team.
Companies in Senolytics & Cellular Rejuvenation
- Unity Biotechnology — Public, $285M
- Rubedo Life Sciences — Series A, $40M
- Oisin Biotechnologies — Seed, $7M
- Cleara Biotech — Seed, $3M
- Cellarity — Series B, $243M
- Senolytic Therapeutics
- Gordian Biotechnology — Series A, $60M
- Deciduous Therapeutics — Seed, $4M
- Cellvie — Seed, $5M
- Elevian — Series A, $21M
- Juvenescence — Series C, $200M
- Selphagy Therapeutics
- Aeovian Pharmaceuticals — Series B, $105M
Frequently Asked Questions
- What companies are in the Senolytics & Cellular Rejuvenation category?
- The Senolytics & Cellular Rejuvenation category includes 13 companies: Unity Biotechnology, Rubedo Life Sciences, Oisin Biotechnologies, Cleara Biotech, Cellarity, Senolytic Therapeutics, Gordian Biotechnology, Deciduous Therapeutics, Cellvie, Elevian, Juvenescence, Selphagy Therapeutics, Aeovian Pharmaceuticals. This is part of the Longevity & Human Enhancement market map maintained by Hartmann Capital.
- How many Senolytics & Cellular Rejuvenation startups are tracked?
- Hartmann Capital tracks 13 companies in the Senolytics & Cellular Rejuvenation segment of the Longevity & Human Enhancement market map.
- What are the best funded Senolytics & Cellular Rejuvenation companies?
- Top funded companies in Senolytics & Cellular Rejuvenation include Unity Biotechnology ($285M), Cellarity ($243M), Juvenescence ($200M), Aeovian Pharmaceuticals ($105M), Gordian Biotechnology ($60M). Browse the full list in the Longevity & Human Enhancement market map.
- How can I submit my startup?
- You can submit your startup for inclusion by visiting the submission page. Submissions are reviewed by Hartmann Capital's research team.